prednisone and Acute Relapsing Multiple Sclerosis

prednisone has been researched along with Acute Relapsing Multiple Sclerosis in 18 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research

Studies (18)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

ARMS (Assessing Relapses in Multiple Sclerosis) TCS Scores (Total Composite Scores)

"Patients completed the ARMS survey after treatment for the new relapse.The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~The TCS score was calculated only for the time point after treatment of relapse. It was a sum of questions 4 (symptom improvement), 5 (ADL), and 6 (return to previous state of health (RSH)) were evaluated. Scores range from 0 to 30 units, with higher scores representing greater improvement/better functioning." (NCT02258217)
Timeframe: Follow-up visit

ARMS (Assessing Relapses in Multiple Sclerosis) ADL Scores (Activities of Daily Living)

"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, history of patients from the survey after treatment for the new relapse will be collected.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~ADL scores were calculated from Part 1 (new relapse), question 3 and Part 2 (after treatment of relapse), question 5 both specifically refer to ADL;~Scale: ADL (Activities of Daily Living) Minimum value: 0 Maximum value: 9 Higher scores indicated better functioning/ improvement." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment

ARMS (Assessing Relapses in Multiple Sclerosis) PCS Scores (Partial Composite Scores)

"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~PCS was computed based on the sum of the ADL and RSH questions. The PCS was computed separately for Part 1 (new relapse) and Part 2 (after relapse treatment) and summarized descriptively; Higher scores indicating better functioning/greater improvement. The PCS scores were on a scale of 0 to 20 units." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment

ARMS (Assessing Relapses in Multiple Sclerosis) RSH Scores (Return to Previous Health)

"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse. The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~Part 1 (new relapse) & Part 2 (after treatment of new relapse), question 6 were used to calculate RSH;~Scale: RSH (Return to previous health) Minimum value: -1 Maximum value: 10 Higher scores indicating a more complete return to previous state of health." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment

EDSS (Expanded Disability Status Scale) Scores.

"This scaling score is obtained by performing a neurologic exam with specific attention to eight different neurologic functional systems: visual, pyramidal, cerebellar, bowel and bladder, cerebral, brainstem, sensory and other (10). The score is rated from zero (normal neurologic examination) to ten (death due to MS). This is the standard neurologic disability scale used in clinical trials for the evaluation of disability in patients with MS.~These scores were compared between pre and post phase using paired t-tests." (NCT02258217)
Timeframe: baseline and at follow-up

GASE Scale Questionnaire (Generic Assessment of Side Effects)

"Patients who reported a history of poor corticosteroid tolerability will be placed on Acthar and GASE scale will be given to assess tolerability to Acthar.~We listed the number of times a symptom was reported and was attributable to the ACTHAR treatment" (NCT02258217)
Timeframe: 1 week

MSIS (Multiple Sclerosis Impact Scale) - 29 Psychological Score.

"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS and 9 questions assess the psychological impact of MS.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The score was on a scale of 9 to 45 points for MSIS psychological score.~Higher score indicate worse outcome." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment

MSIS (Multiple Sclerosis Impact Scale) -29 Physical Score

"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS.~The physical impact of MS was compared between pre and post phase using paired t-tests. Each question is answered with points ranging from 1 to 5. Higher score indicates worse outcome. The total MSIS physical score ranges from 20 to 100 points with lower points indicating better impact." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment

SAGE (Self-administered Gerocognitive Exam) Scores

"The Self-Administered Gerocognitive Exam (SAGE) is designed to detect early signs of cognitive, memory or thinking impairments. It evaluates your thinking abilities and helps physicians to know how well your brain is working.~It consists of 12 questions which are scored at different scales. The final SAGE score is calculated as a sum of these 12 questions and it ranges from 0 to 22.~Higher score indicates better outcome." (NCT02258217)
Timeframe: baseline and follow-up

Reviews

2 reviews available for prednisone and Acute Relapsing Multiple Sclerosis

Trials

6 trials available for prednisone and Acute Relapsing Multiple Sclerosis

Other Studies

10 other studies available for prednisone and Acute Relapsing Multiple Sclerosis